#investEU - Curetis obtains EIB debt financing totaling up to EUR 25 million to further expand its diagnostic platform
(Thomson Reuters ONE) -
Curetis /
#investEU - Curetis obtains EIB debt financing totaling up to EUR 25 million to
further expand its diagnostic platform
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
PRESS RELEASE
#investEU - Curetis obtains EIB debt financing totaling up to EUR 25 million to
further expand its diagnostic platform
* European Investment Bank (EIB) provides EUR 10 million immediately, with a
further EUR 15 million available upon meeting certain milestones
* Transaction is guaranteed by the European Fund for Strategic Investments
(EFSI), the heart of the Investment Plan for Europe
* Financing allows strategic expansion and further development of Unyvero
Platform
Amsterdam, the Netherlands, Holzgerlingen, Germany, and Luxembourg, 12 December
2016-
Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a
developer of next-level molecular diagnostic solutions, and the European
Investment Bank (EIB) today announced that the EIB granted Curetis a EUR 25
million senior, unsecured loan. The financing is the first growth capital loan
under the European Growth Finance Facility (EGFF), launched in November 2016. It
is backed by a guarantee from the European Fund for Strategic Investments
(EFSI). EFSI is an essential pillar of the Investment Plan for Europe (IPE),
under which the EIB and the European Commission are working as strategic
partners to support investments and bring back jobs and growth to Europe.
The debt facility features typical market interest rates with more than half of
the interest payments deferred into the repayment at maturity. The funding can
be drawn in up to five tranches within the next 24 months; each tranche is to be
repaid upon maturity five years after draw-down. The flexible terms allow
Curetis to fund up to 50% of its expected medium-term R&D project requirements
(incl. R&D staff costs, external R&D operating expenses, corresponding capital
expenditures for R&D etc.) and will enable Curetis to fund the strategic
expansion and enhancement of its Unyvero Platform and products.
Specifically, the funds will allow the further development and validation of
complementary technology assets and corresponding IP and the funding of clinical
trials. In addition, the funds will support the integration of the recently
acquired GEAR database and assets.
"We are proud to get the support of the EIB," said Dr. Oliver Schacht, CEO of
Curetis. "The funding will allow us to further expand our leading position in
molecular diagnostics by integrating complementary know-how and assets into our
proprietary Unyvero Platform. Moreover, we will be able to significantly
accelerate our R&D activities and develop a broader pipeline of applications for
our Unyvero platform."
EIB Vice President Ambroise Fayolle, responsible for Germany and innovation in
the EU Bank, emphasized: "This transaction demonstrates EIB's firm commitment to
support early-stage and fast-growing companies in Europe. Supporting R&D is one
of the EIB's key goals, and small midcaps like Curetis are instrumental for
Europe's knowledge economy, as they pursue innovation-intensive businesses and
employ highly qualified people. Most importantly, this investment will
contribute to accelerating the development and market launch of new diagnostics
tests, helping to improve the diagnosis and survival rates of critically ill
patients in Europe as well as to counteract increasing antibiotic resistance."
European Commission Vice-President Jyrki Katainen, responsible for Jobs, Growth,
Investment and Competitiveness, said: "The EFSI is playing a crucial role in
ensuring that innovative smaller businesses have access to the finance they need
to fund their research activities. Curetis is undertaking cutting-edge research
on advanced diagnostics. The EFSI can help firms like Curetis reach the next
level, while ensuring that Europe maintains its status as a centre of innovate
healthcare product development."
Disclaimer
CAUTION - Investigational device. Limited by Federal (or United States) law to
investigational use. The information contained in this communication does not
constitute nor imply an offer to sell or transfer any product, and no product
based on the Curetis Unyvero technology is currently available for sale in the
United States of America or Canada. The analytical and clinical performance
characteristics of any Curetis Unyvero product which may be sold at some future
point in time in the U.S. have not yet been established.
Note to the editor:
About the European Investment Bank
The European Investment Bank (EIB) is the long-term lending institution of the
European Union, owned by its Member States. It makes long-term finance available
for sound investment in order to contribute towards EU policy goals.
The Investment Plan for Europe
In December 2014, the EU Heads of State or Government decided to launch a
EUR 315bn investment offensive. With this initiative, the EU Member States are
addressing the continued lack of investment and innovation within the Union. The
EIB Group, consisting of the European Investment Bank and the European
Investment Fund, is playing a vital role in this investment drive. Through
guarantees from the European Fund for Strategic Investments (EFSI), the EIB
Group is able to take on a higher share of project risk, encouraging private
finance providers to participate in the projects. Up to now, nearly 400
operations have been mounted with EFSI support, which are expected to mobilize a
total investment of more than EUR 150bn. EFSI is supported by a new advisory
service, the European Investment Advisory Hub, which will enable public and
private project operators to structure their investment projects more
professionally. The investment offensive also aims to make the regulatory
environment in the EU more conducive to investment, especially in the digital,
energy and capital market sectors.
About Curetis
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the
development and commercialization of reliable, fast and cost-effective products
for diagnosing severe infectious diseases. The diagnostic solutions of Curetis
enable rapid multi-parameter pathogen and antibiotic resistance marker detection
in only a few hours, a process that today can take up to days or even weeks with
other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and
Euronext Brussels and private equity funds of over EUR 63.5 million.
Furthermore, Curetis has entered into a debt financing facility with EIB for up
to EUR 25 million. The company is based in Holzgerlingen near Stuttgart,
Germany. Curetis has signed collaboration agreements with Heraeus Medical and
Cempra Inc. as well as several international distribution agreements covering
many countries across Europe, the Middle East and Asia.
For further information, please visit www.curetis.com.
Legal Disclaimer
This document constitutes neither an offer to buy nor to subscribe securities
and neither this document nor any part of it should form the basis of any
investment decision in Curetis.
The information contained in this press release has been carefully prepared.
However, Curetis bears and assumes no liability of whatever kind for the
correctness and completeness of the information provided herein. Curetis does
not assume an obligation of whatever kind to update or correct information
contained in this press release whether as a result of new information, future
events or for other reasons.
This press release includes statements that are, or may be deemed to be,
"forward-looking statements". These forward-looking statements can be identified
by the use of forward-looking terminology, including the terms "believes",
"estimates", "anticipates", "expects", "intends", "may", "will", or "should",
and include statements Curetis makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks and
uncertainties and readers are cautioned that any such forward-looking statements
are not guarantees of future performance. Curetis' actual results may differ
materially from those predicted by the forward-looking statements. Curetis
undertakes no obligation to publicly update or revise forward-looking
statements, except as may be required by law.
Contact details
Curetis Contacts
Curetis
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr(at)curetis.com or ir(at)curetis.com
www.curetis.com - www.unyvero.com
International Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info((at))akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
U.S. Media & Investor Inquiries
The Ruth Group
Lee Roth
lroth(at)theruthgroup.com
Tel. +1 646 536 7012
Press contact EIB:
Christof Roche, c.roche(at)eib.org, tel.: +352 43 79 89013 / Mobile:
+32 479 65 05 88
Website: www.eib.org/press - Press Office: +352 4379 21000 - press(at)eib.org
Follow us on Twitter (at)eib
Curetis_Logo:
http://hugin.info/171382/R/2064051/774579.jpg
20161212_Curetis_PR_EN:
http://hugin.info/171382/R/2064051/774614.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Curetis via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 12.12.2016 - 16:37 Uhr
Sprache: Deutsch
News-ID 512314
Anzahl Zeichen: 11155
contact information:
Town:
Holzgerlingen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 187 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"#investEU - Curetis obtains EIB debt financing totaling up to EUR 25 million to further expand its diagnostic platform"
steht unter der journalistisch-redaktionellen Verantwortung von
Curetis (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
